Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 19 h ago

Forte Biosciences, Inc.: GLAZER CAPITAL, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Glazer Capital, LLC amended its Schedule 13G filing on Forte Biosciences, Inc. with the SEC under accession number 0001076809-26-000165. The amendment updates the investment firm's reported beneficial ownership stake in the clinical-stage biopharmaceutical company. Schedule 13G filings are required of investors holding passive stakes above 5% of a company's shares, and amendments typically reflect changes in position size or reporting status. The exact revised share count and percentage were not disclosed in the filing headline. Investors will watch for further 13G or 13D filings to gauge Glazer's conviction in Forte, whose share price has historically been sensitive to shifts in institutional ownership.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Forte Biosciences, Inc., Glazer Capital, LLC